All In Biotech

Investigational drug · Phase 3

Telisotuzumab Adizutecan

Also called: ABBV-400

Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

16

16 still active

All registered trials

18

Any phase or sponsor naming "Telisotuzumab Adizutecan"

First trial start

2023

Nov 12, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Telisotuzumab Adizutecan", any sponsor or status.

Conditions studied

As listed on its trial records.

  • c-MET
  • Non-Squamous Non-Small Cell Lung Cancer
  • Metastatic Colorectal Cancer
  • Colorectal Cancer
  • Solid Tumors Harboring MET Amplification
  • Head and Neck Squamous Cell Carcinoma
  • Unresectable Metastatic Colorectal Cancer
  • Non Small Cell Lung Carcinoma
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • PDAC

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Head and neck cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Telisotuzumab Adizutecan" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for c-MET

  • BudigalimabABBV-181Phase 36 trials

    AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.